1-2 of 2
Joel Guigay
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Caroline Even, Hung-Ming Wang, Shau-Hsuan Li, Roger K-C Ngan, Arunee Dechaphunkul, Li Zhang, Chia-Jui Yen, Po Chung Chan, Somvilai Chakrabandhu, Brigette B.Y. Ma, Suebpong Tanasanvimon, Victor H.F. Lee, Pei-Jen Lou, Zujun Li, Alexander I. Spira, Ammar Sukari, Joël Guigay, Steven McCune, Juan Gonzalez-Maffe, Sebastian Szpakowski, Yao Yao, Hongzi Liang, Jennifer Mataraza, Romain Séchaud, Luigi Manenti, Darren W-T. Lim
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6413–6423.
https://doi.org/10.1158/1078-0432.CCR-21-0822
Published: 01 December 2021
View article titled, Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
Open the PDF for Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer in another window
Includes: Supplementary data
Journal Articles

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

Robert L. Ferris, Lisa Licitra, Jerome Fayette, Caroline Even, George Blumenschein, Jr, Kevin J. Harrington, Joel Guigay, Everett E. Vokes, Nabil F. Saba, Robert Haddad, Shanmugasundaram Ramkumar, Jeffery Russell, Peter Brossart, Makoto Tahara, A. Dimitrios Colevas, Fernando Concha-Benavente, Mark Lynch, Li Li, Maura L. Gillison
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (17): 5221–5230.
https://doi.org/10.1158/1078-0432.CCR-18-3944
Published: 03 September 2019
View article titled, Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
Open the PDF for Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use in another window
Includes: Supplementary data